Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076268045> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2076268045 abstract "Topotecan (Hycamtin) is a water soluble semisynthetic analogue of the alkaloid camptothecin which has antitumour activity in preclinical models in vitro and in vivo. A range of Phase I studies has been performed and a daily x 5 iv. schedule, which showed most promising evidence of activity, was selected for extensive clinical evaluation. To date, topotecan has been shown to be active in a number of malignancies, including metastatic ovarian cancer, recurrent small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer and myelodysplastic syndrome. In ovarian cancer, response rates of around 15% were identified in patients who had failed standard chemotherapy, and in a randomised, comparative study with paclitaxel response rates of 20% (topotecan) and 13% (paclitaxel) were observed. In addition, overall time to progression was impressive at 23 weeks (topotecan) compared with 14 weeks (paclitaxel). In recurrent SCLC, topotecan has shown good activity in sensitive patients with a response rate of 39%, although the response rate in refractory patients was considerably lower (7%). Median survival of all patients was 5.4 months, acceptable for this difficult clinical scenario. Topotecan is well-tolerated in the majority of patients and subjective toxicities are uncommon. The principal side-effect is myelosuppression, mainly neutropenia. Serious clinical sequelae are relatively uncommon and non-cumulative. Nonhaematological toxicities are generally mild and not dose-limiting. In clinical use, topotecan has exhibited activity in multiple tumour types, with a side-effect profile that is predictable and manageable. The drug is under evaluation in other tumour types and in combination chemotherapy regimens." @default.
- W2076268045 created "2016-06-24" @default.
- W2076268045 creator A5002298911 @default.
- W2076268045 creator A5080571689 @default.
- W2076268045 date "1997-05-01" @default.
- W2076268045 modified "2023-09-24" @default.
- W2076268045 title "Topotecan, an active new antineoplastic agent: review and current status" @default.
- W2076268045 cites W1845622004 @default.
- W2076268045 cites W1883759477 @default.
- W2076268045 cites W1905580151 @default.
- W2076268045 cites W1926104136 @default.
- W2076268045 cites W1952431753 @default.
- W2076268045 cites W1964502819 @default.
- W2076268045 cites W1972483602 @default.
- W2076268045 cites W1980326764 @default.
- W2076268045 cites W1982754402 @default.
- W2076268045 cites W1994520646 @default.
- W2076268045 cites W2020057881 @default.
- W2076268045 cites W2048888451 @default.
- W2076268045 cites W2054837357 @default.
- W2076268045 cites W2056110230 @default.
- W2076268045 cites W2060932390 @default.
- W2076268045 cites W2066933615 @default.
- W2076268045 cites W2078437185 @default.
- W2076268045 cites W2087036937 @default.
- W2076268045 cites W2089750858 @default.
- W2076268045 cites W2095355415 @default.
- W2076268045 cites W2103786242 @default.
- W2076268045 cites W2108018389 @default.
- W2076268045 cites W2134680286 @default.
- W2076268045 cites W2257426985 @default.
- W2076268045 cites W2260476654 @default.
- W2076268045 cites W2277186606 @default.
- W2076268045 cites W2316156427 @default.
- W2076268045 cites W2416555132 @default.
- W2076268045 doi "https://doi.org/10.1517/13543784.6.5.593" @default.
- W2076268045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15989623" @default.
- W2076268045 hasPublicationYear "1997" @default.
- W2076268045 type Work @default.
- W2076268045 sameAs 2076268045 @default.
- W2076268045 citedByCount "16" @default.
- W2076268045 countsByYear W20762680452015 @default.
- W2076268045 countsByYear W20762680452017 @default.
- W2076268045 countsByYear W20762680452020 @default.
- W2076268045 crossrefType "journal-article" @default.
- W2076268045 hasAuthorship W2076268045A5002298911 @default.
- W2076268045 hasAuthorship W2076268045A5080571689 @default.
- W2076268045 hasConcept C121608353 @default.
- W2076268045 hasConcept C126322002 @default.
- W2076268045 hasConcept C143998085 @default.
- W2076268045 hasConcept C2776256026 @default.
- W2076268045 hasConcept C2776694085 @default.
- W2076268045 hasConcept C2777292972 @default.
- W2076268045 hasConcept C2779682216 @default.
- W2076268045 hasConcept C2780427987 @default.
- W2076268045 hasConcept C2781209748 @default.
- W2076268045 hasConcept C55493867 @default.
- W2076268045 hasConcept C71924100 @default.
- W2076268045 hasConcept C86803240 @default.
- W2076268045 hasConcept C98274493 @default.
- W2076268045 hasConceptScore W2076268045C121608353 @default.
- W2076268045 hasConceptScore W2076268045C126322002 @default.
- W2076268045 hasConceptScore W2076268045C143998085 @default.
- W2076268045 hasConceptScore W2076268045C2776256026 @default.
- W2076268045 hasConceptScore W2076268045C2776694085 @default.
- W2076268045 hasConceptScore W2076268045C2777292972 @default.
- W2076268045 hasConceptScore W2076268045C2779682216 @default.
- W2076268045 hasConceptScore W2076268045C2780427987 @default.
- W2076268045 hasConceptScore W2076268045C2781209748 @default.
- W2076268045 hasConceptScore W2076268045C55493867 @default.
- W2076268045 hasConceptScore W2076268045C71924100 @default.
- W2076268045 hasConceptScore W2076268045C86803240 @default.
- W2076268045 hasConceptScore W2076268045C98274493 @default.
- W2076268045 hasLocation W20762680451 @default.
- W2076268045 hasLocation W20762680452 @default.
- W2076268045 hasOpenAccess W2076268045 @default.
- W2076268045 hasPrimaryLocation W20762680451 @default.
- W2076268045 hasRelatedWork W1549846058 @default.
- W2076268045 hasRelatedWork W1913802169 @default.
- W2076268045 hasRelatedWork W1952453258 @default.
- W2076268045 hasRelatedWork W2018185888 @default.
- W2076268045 hasRelatedWork W2066933615 @default.
- W2076268045 isParatext "false" @default.
- W2076268045 isRetracted "false" @default.
- W2076268045 magId "2076268045" @default.
- W2076268045 workType "article" @default.